Vinorelbine — Drug Intelligence | 36 EU Trials

Filter these 36 trials by condition, phase, country and more.

Open in Search →

36 Registered trials

15 Recruiting

16 Completed trials

27 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase III: 16 Phase II/III: 1 Phase II: 11 Phase I/II: 6 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Non-small cell lung cancer 4 Diffuse large B-cell lymphoma 4 Breast cancer 2 Non-small cell lung cancer stage IV 2 Breast cancer metastatic 2 Ewing's sarcoma 2 Non-small cell lung cancer stage III 1 Ovarian cancer recurrent 1 Chronic lymphocytic leukaemia 1 Mantle cell lymphoma 1 Non-small cell lung cancer stage I 1 Ovarian cancer 1

Sponsors using this IMP

AstraZeneca AB 4 F. Hoffmann-La Roche AG 3 Fondazione Italiana Linfomi Ets 3 Genmab A/S 2 Institut Gustave Roussy 2 Intergroupe Francophone De Cancerologie Thoracique 2 Alx Oncology Inc. 1 Azienda Ospedaliera Universitaria Meyer IRCCS 1 Bristol Myers Squibb International Corporation 1 Champalimaud Clinical Centre 1 Fondazione Santobono Pausilipon Onlus 1 GPOH gGmbH 1

All trials — page 2

36 total

Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Phase III 11 countries Incyte Corp.
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Phase I/II 9 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended

2024-511641-18-00 Phase II 1 country Fondazione Italiana Linfomi Ets
A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re… Ended

2023-506861-76-00 Phase III 10 countries F. Hoffmann-La Roche AG
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Ended

2024-515326-83-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended

2023-505981-26-00 Phase III 9 countries F. Hoffmann-La Roche AG
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended

2023-503813-31-01 Phase III 13 countries Seagen Inc.
A dose-esalation phase I/II study in patients with RAS-mutated metastatic colorectal cancer to investigate safety and clinical actvitiy of t… Ended

2023-509732-25-00 Phase I (FiH) 1 country Universitair Medisch Centrum Utrecht
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (… Ended

2024-516904-40-00 Phase III 8 countries F. Hoffmann-La Roche AG
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Phase III 4 countries Bristol-Myers Squibb International Corporation

Showing 25–36 of 36 trials

← All drugs A–Z